BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV;  NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713-1722. [PMID: 22241899 DOI: 10.1093/annonc/mdr561] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 141] [Article Influence: 13.7] [Reference Citation Analysis]
2 Lin C, Zhao GC, Xu YD, Wang DS, Jin DY, Ji Y, Lou WH, Wu WC. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Oncotarget 2016;7:60657-64. [PMID: 27447976 DOI: 10.18632/oncotarget.10630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang R, Chen Z, He L, He N, Xi Z, Li Z, Deng Y, Zeng X. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application. Theranostics 2017;7:3559-72. [PMID: 28912895 DOI: 10.7150/thno.20797] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
4 Rawat M, Kadian K, Gupta Y, Kumar A, Chain PSG, Kovbasnjuk O, Kumar S, Parasher G. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes (Basel) 2019;10:E752. [PMID: 31557962 DOI: 10.3390/genes10100752] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
5 Xiang JF, Wang WQ, Liu L, Xu HX, Wu CT, Yang JX, Qi ZH, Wang YQ, Xu J, Liu C, Long J, Ni QX, Li M, Yu XJ. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL. Sci Rep 2016;6:19222. [PMID: 26753987 DOI: 10.1038/srep19222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
6 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Reference Citation Analysis]
7 Lee JW, Lee JH, Park Y, Kwon J, Lee W, Song KB, Hwang DW, Kim SC. Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma. J Clin Med 2021;10:1345. [PMID: 33805079 DOI: 10.3390/jcm10071345] [Reference Citation Analysis]
8 Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016;16:1057-62. [DOI: 10.1016/j.pan.2016.09.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
9 Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, Klee EW, Smyrk TC, Bamlet W, Han JJ. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology. 2012;143:1510-1517.e1. [PMID: 22960655 DOI: 10.1053/j.gastro.2012.08.044] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 9.8] [Reference Citation Analysis]
10 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
11 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
12 Piagnerelli R, Marrelli D, Roviello G, Ferrara F, Di Mare G, Voglino C, Petrioli R, Marini M, Macchiarelli R, Roviello F. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas. Tumour Biol 2016;37:1959-66. [PMID: 26334620 DOI: 10.1007/s13277-015-3986-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, Marchetti P, Ziparo V, Ramacciato G. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 2014;8:102-8. [PMID: 24516708 DOI: 10.5009/gnl.2014.8.1.102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
14 O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 2013;107:78-85. [PMID: 22886586 DOI: 10.1002/jso.23230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
15 Rubinson DA, Wolpin BM. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:761-76. [PMID: 26226909 DOI: 10.1016/j.hoc.2015.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
16 Macías N, Sayagués JM, Esteban C, Iglesias M, González LM, Quiñones-Sampedro J, Gutiérrez ML, Corchete LA, Abad MM, Bengoechea O, Muñoz-Bellvis L. Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. J Clin Gastroenterol 2018;52:e11-7. [PMID: 28059940 DOI: 10.1097/MCG.0000000000000793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
17 Xu HX, Li S, Wu CT, Qi ZH, Wang WQ, Jin W, Gao HL, Zhang SR, Xu JZ, Liu C, Long J, Xu J, Ni QX, Yu XJ, Liu L. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology 2018;18:671-7. [PMID: 30153903 DOI: 10.1016/j.pan.2018.05.479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Pan P, Skaer C, Yu J, Zhao H, Ren H, Oshima K, Wang LS. Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. J Berry Res 2017;7:147-61. [PMID: 29367867 DOI: 10.3233/JBR-170159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
19 Wojtalewicz N, Sadeqzadeh E, Weiß JV, Tehrani MM, Klein-Scory S, Hahn S, Schmiegel W, Warnken U, Schnölzer M, de Bock CE, Thorne RF, Schwarte-Waldhoff I. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PLoS One 2014;9:e90461. [PMID: 24625754 DOI: 10.1371/journal.pone.0090461] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
20 Narita Y, Taniguchi H, Komori A, Nitta S, Yamaguchi K, Kondo C, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol. 2014;73:409-416. [PMID: 24322376 DOI: 10.1007/s00280-013-2367-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
21 Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) 2015;17:942-52. [PMID: 26255895 DOI: 10.1111/hpb.12448] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
22 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
23 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Luo Y, Zhu H, Tan T, He J. Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors. Front Pharmacol 2018;9:963. [PMID: 30250431 DOI: 10.3389/fphar.2018.00963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ko J, Lim HB. Multicore Magnetic Nanoparticles (MMNPs) Doped with Cs and FITC for the Determination of Biomarker in Serum using ICP-MS. Anal Chem 2014;86:4140-4. [DOI: 10.1021/ac4036668] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
26 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
27 Kim H, Kang KN, Shin YS, Byun Y, Han Y, Kwon W, Kim CW, Jang JY. Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1443. [PMID: 32492943 DOI: 10.3390/cancers12061443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 8.4] [Reference Citation Analysis]
29 Huang Z, Li Z, Jiang M, Liu R, Lv Y. Homogeneous Multiplex Immunoassay for One-Step Pancreatic Cancer Biomarker Evaluation. Anal Chem 2020;92:16105-12. [DOI: 10.1021/acs.analchem.0c03780] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
30 Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014; 20(31): 10802-10812 [PMID: 25152583 DOI: 10.3748/wjg.v20.i31.10802] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
31 Reiter MJ, Costello JE, Schwope RB, Lisanti CJ, Osswald MB. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. J Comput Assist Tomogr 2015;39:825-34. [PMID: 26248153 DOI: 10.1097/RCT.0000000000000297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
32 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
33 Luo G, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett 2017;13:881-6. [PMID: 28356973 DOI: 10.3892/ol.2016.5501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, Mochizuki A, Goodenowe DB. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 2015; 21(21): 6604-6612 [PMID: 26074698 DOI: 10.3748/wjg.v21.i21.6604] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
35 He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, Li S. Preoperative CEA levels are supplementary to CA19-9 Levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer. 2018;9:3117-3128. [PMID: 30210635 DOI: 10.7150/jca.25339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
36 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo 2018;32:1533-40. [PMID: 30348713 DOI: 10.21873/invivo.11411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 Lennon KM, Wakefield DL, Maddox AL, Brehove MS, Willner AN, Garcia-Mansfield K, Meechoovet B, Reiman R, Hutchins E, Miller MM, Goel A, Pirrotte P, Van Keuren-Jensen K, Jovanovic-Talisman T. Single molecule characterization of individual extracellular vesicles from pancreatic cancer. J Extracell Vesicles 2019;8:1685634. [PMID: 31741725 DOI: 10.1080/20013078.2019.1685634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
38 Thomas RM, Truty MJ, Kim M, Kang Y, Zhang R, Chatterjee D, Katz MH, Fleming JB. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2015;22:1884-92. [PMID: 25404477 DOI: 10.1245/s10434-014-4241-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
39 Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
40 Salmiheimo A, Mustonen H, Stenman UH, Puolakkainen P, Kemppainen E, Seppänen H, Haglund C. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. PLoS One 2016;11:e0163064. [PMID: 27632196 DOI: 10.1371/journal.pone.0163064] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
41 Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLoS Med 2020;17:e1003489. [PMID: 33301466 DOI: 10.1371/journal.pmed.1003489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Reames BN, Blair AB, Krell RW, Groot VP, Gemenetzis G, Padussis JC, Thayer SP, Falconi M, Wolfgang CL, Weiss MJ, Are C, He J. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Ann Surg. 2019;. [PMID: 31449138 DOI: 10.1097/sla.0000000000003568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
44 Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017;19:667-81. [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
45 Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-220. [PMID: 30718832 DOI: 10.1038/s41575-019-0109-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 176] [Article Influence: 68.0] [Reference Citation Analysis]
46 Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34. [PMID: 23026552 DOI: 10.1016/j.jprot.2012.09.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
47 López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 2021;247:104329. [PMID: 34298186 DOI: 10.1016/j.jprot.2021.104329] [Reference Citation Analysis]
48 Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971-976. [PMID: 30131287 DOI: 10.1016/j.pan.2018.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
49 Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2019;25:868-80. [PMID: 30352909 DOI: 10.1158/1078-0432.CCR-18-1650] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
50 Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY) 2019;44:1575-600. [PMID: 30498924 DOI: 10.1007/s00261-018-1845-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
51 George B, Kent M, Surinach A, Lamarre N, Cockrum P. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:754687. [PMID: 34671563 DOI: 10.3389/fonc.2021.754687] [Reference Citation Analysis]
52 Tang X, Zhang M, Sun L, Xu F, Peng X, Zhang Y, Deng Y, Wu S. The Biological Function Delineated Across Pan-Cancer Levels Through lncRNA-Based Prognostic Risk Assessment Factors for Pancreatic Cancer. Front Cell Dev Biol 2021;9:694652. [PMID: 34195204 DOI: 10.3389/fcell.2021.694652] [Reference Citation Analysis]
53 Fackche N, Schmocker RK, Kubi B, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Powers B, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Gamblin TC, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB. The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. J Gastrointest Surg 2021. [PMID: 33634422 DOI: 10.1007/s11605-021-04953-y] [Reference Citation Analysis]
54 Chou A, Waddell N, Cowley MJ, Gill AJ, Chang DK, Patch AM, Nones K, Wu J, Pinese M, Johns AL. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013;5:78. [PMID: 24004612 DOI: 10.1186/gm482] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 7.7] [Reference Citation Analysis]
55 Onoe S, Yokoyama Y, Kokuryo T, Igami T, Mizuno T, Yamaguchi J, Watanabe N, Kawakatsu S, Ebata T. A presurgical prognostic stratification based on nutritional assessment and carbohydrate antigen 19-9 in pancreatic carcinoma: An approach with nonanatomic biomarkers. Surgery 2021;169:1463-70. [PMID: 33423799 DOI: 10.1016/j.surg.2020.11.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, Andrikou K, Muffatti F, Balzano G, Reni M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533-1539. [PMID: 27423449 DOI: 10.1016/j.ejso.2016.06.398] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
57 Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, Hirakawa K, Ohira M. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 2017;15:16. [PMID: 28069033 DOI: 10.1186/s12957-016-1078-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
58 Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2015;94:e751. [PMID: 25984661 DOI: 10.1097/md.0000000000000751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
59 Lee W, Park Y, Kwon JW, Jun E, Song KB, Lee JH, Hwang DW, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY, Park SY, Kim SC. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. J Clin Med 2020;9:E1477. [PMID: 32423123 DOI: 10.3390/jcm9051477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Gleeson EM, Leigh N, Golas BJ, Magge D, Sarpel U, Hiotis SP, Labow DM, Pintova S, Cohen NA. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer. Pancreas 2021;50:1163-8. [PMID: 34714279 DOI: 10.1097/MPA.0000000000001881] [Reference Citation Analysis]
61 Yee NS, Zhang S, He HZ, Zheng SY. Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. Biomedicines 2020;8:E581. [PMID: 33297544 DOI: 10.3390/biomedicines8120581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
62 Hu H, Qu C, Tang B, Liu W, Ma Y, Chen Y, Xie X, Zhuang Y, Gao H, Tian X, Yang Y. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis. Chin J Cancer Res 2021;33:457-69. [PMID: 34584371 DOI: 10.21147/j.issn.1000-9604.2021.04.03] [Reference Citation Analysis]
63 Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, Akita H, Hama N, Wada H, Kobayashi S, Nonaka Y, Takamatsu S, Shinzaki S, Kumada T, Satomura S, Ito T, Serada S, Naka T, Mori M, Doki Y, Miyoshi E, Nagano H. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Pancreas 2015;44:93-8. [PMID: 25058884 DOI: 10.1097/MPA.0000000000000205] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
64 Guillén-ponce C, Blázquez J, González I, de-Madaria E, Montáns J, Carrato A. Diagnosis and staging of pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1205-16. [DOI: 10.1007/s12094-017-1681-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
65 Wang T, Matsuda Y, Nonaka K, Kakizaki M, Ishiwata T, Kanazawa N, Uegaki S, Muramatsu M, Sawabe M, Mori S, Tanaka M, Kitagawa M, Arai T. Clinicopathological characteristics of gastric cancer with carbohydrate antigen 19-9 expression occurring in elderly individuals: An autopsy study. Pathol Int 2020;70:92-100. [PMID: 31867815 DOI: 10.1111/pin.12882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Qiu H, Wild AT, Wang H, Fishman EK, Hruban RH, Laheru DA, Kumar R, Hacker-Prietz A, Tuli R, Tryggestad E, Schulick RD, Cameron JL, Edil BH, Pawlik TM, Wolfgang CL, Herman JM. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol 2012;104:167-72. [PMID: 22883106 DOI: 10.1016/j.radonc.2012.07.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
67 Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of Pancreatic Cancer. Cancer J. 2015;21:188-193. [PMID: 26049698 DOI: 10.1097/ppo.0000000000000109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
68 Moon D, Kim H, Han Y, Byun Y, Choi Y, Kang J, Kwon W, Jang JY. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2020. [PMID: 33063453 DOI: 10.1002/jhbp.845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Wang SL, Cao S, Sun YN, Wu R, Chi F, Tang MY, Jin XY, Chen XD. Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. Abdom Imaging 2015;40:3117-21. [PMID: 26350284 DOI: 10.1007/s00261-015-0544-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
70 Zakaria H, Sallam AN, Ayoub II, Gad EH, Taha M, Roshdy MR, Sweed D, Gaballa NK, Yassein T. Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma. A retrospective cohort study. Ann Med Surg (Lond) 2020;57:321-7. [PMID: 32874564 DOI: 10.1016/j.amsu.2020.07.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Wu L, Zhu L, Xu K, Zhou S, Zhou Y, Zhang T, Hang J, Zee BC. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. J Cancer 2021;12:1715-21. [PMID: 33613759 DOI: 10.7150/jca.50317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Kakar S, Pawlik TM, Allen PJ, Vauthey J. Exocrine Pancreas. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 337-47. [DOI: 10.1007/978-3-319-40618-3_28] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
74 Hue JJ, Markt SC, Sugumar K, Kyasaram RK, Shanahan J, Rothermel LD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Am J Surg 2021:S0002-9610(21)00564-X. [PMID: 34642044 DOI: 10.1016/j.amjsurg.2021.10.001] [Reference Citation Analysis]
75 Kim J, Lee YS, Hwang IK, Kang BK, Cho JY, Yoon YS, Han HS, Hwang JH. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. J Korean Med Sci 2015;30:259-63. [PMID: 25729247 DOI: 10.3346/jkms.2015.30.3.259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
76 Su W, Ren S, Zhu X, Zhang H, Zuo C. Standardized thresholds of volume-based PET/CT parameters predicting survival of patients with pancreatic head cancer treated with stereotactic body radiation therapy. Ann Nucl Med 2020;34:379-87. [PMID: 32277421 DOI: 10.1007/s12149-020-01454-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018;2018:5389820. [PMID: 30186820 DOI: 10.1155/2018/5389820] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
78 Yu J, Lang Q, Zhong C, Wang S, Tian Y. Genome-Wide Identification of Autophagy Prognostic Signature in Pancreatic Cancer. Dose Response 2021;19:15593258211023260. [PMID: 34262410 DOI: 10.1177/15593258211023260] [Reference Citation Analysis]
79 Ishimoto U, Kinoshita A, Hirose Y, Shibata K, Ishii A, Shoji R, Yokota T, Iwaku A, Mizuno Y, Koike K, Saruta M. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol 2019;84:647-54. [DOI: 10.1007/s00280-019-03895-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
80 Lin C, Wu WC, Zhao GC, Wang DS, Lou WH, Jin DY. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4527. [PMID: 27495108 DOI: 10.1097/MD.0000000000004527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
81 Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020;271:740-747. [PMID: 30312198 DOI: 10.1097/sla.0000000000003049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
82 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
83 Boeck S, Wittwer C, Heinemann V, Haas M, Kern C, Stieber P, Nagel D, Holdenrieder S. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer. 2013;108:1684-1694. [PMID: 23579210 DOI: 10.1038/bjc.2013.158] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
84 Xiao J, Wang L, Hong T, Li B, Liu W, Qu Q, Zheng C, He X. The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study. J Oncol 2021;2021:5829893. [PMID: 33688345 DOI: 10.1155/2021/5829893] [Reference Citation Analysis]
85 Wang QH, Ji ZG, Chen ZG, Li HZ, Fan H, Fan XR, Shi BB, Fang Y. Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer. Int J Surg. 2015;15:113-116. [PMID: 25647541 DOI: 10.1016/j.ijsu.2015.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
86 Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, Doki Y, Mori M, Jin W. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416. [PMID: 24024929 DOI: 10.1186/1471-2407-13-416] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
87 Guerrero PE, Duran A, Ortiz MR, Castro E, Garcia-Velasco A, Llop E, Peracaula R. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. J Proteomics 2021;231:104004. [PMID: 33038510 DOI: 10.1016/j.jprot.2020.104004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
89 Jazieh KA, Foote MB, Diaz LA Jr. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol 2014;24:67-76. [PMID: 24635863 DOI: 10.1016/j.semradonc.2013.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
90 Vitello DJ, Bentrem DJ. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. J Surg Oncol 2021;123:1449-59. [PMID: 33831249 DOI: 10.1002/jso.26369] [Reference Citation Analysis]
91 Ferreira JA, Peixoto A, Neves M, Gaiteiro C, Reis CA, Assaraf YG, Santos LL. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates 2016;24:34-54. [DOI: 10.1016/j.drup.2015.11.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 13.3] [Reference Citation Analysis]
92 Liu L, Xu HX, He M, Wang W, Wang WQ, Wu CT, Wei RQ, Liang Y, Gao HL, Liu C, Xu J, Long J, Ni QX, Shao CH, Wang J, Yu XJ. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. Surgery 2018;163:1280-94. [PMID: 29548773 DOI: 10.1016/j.surg.2018.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
93 Zhou G, Liu X, Wang X, Jin D, Chen Y, Li G, Li C, Fu D, Xu W, Wang X. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther 2017;10:1199-206. [PMID: 28280354 DOI: 10.2147/OTT.S116136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
94 Mokdad AA, Minter RM, Zhu H, Mansour JC, Choti MA, Polanco PM. Reply to J. Bergquist et al and T.-Y. Lai et al. JCO 2017;35:1624-5. [DOI: 10.1200/jco.2016.71.3891] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
95 Li S, Xu H, Wu C, Wang W, Jin W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Liu L. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med 2019;8:572-84. [PMID: 30632317 DOI: 10.1002/cam4.1957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
96 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Sci Rep 2021;11:20797. [PMID: 34675229 DOI: 10.1038/s41598-021-00060-9] [Reference Citation Analysis]
97 Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681-689. [PMID: 23315099 DOI: 10.1007/s00432-012-1371-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
98 Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. [PMID: 23247983 DOI: 10.1245/s10434-012-2809-1] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 14.6] [Reference Citation Analysis]
99 O'Reilly EM, Lowery MA. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J 2012;18:609-13. [PMID: 23187849 DOI: 10.1097/PPO.0b013e3182758e27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
100 Li J, Li Z, Kan H, Sun Z, Xing J, Cheng Y, Bai C. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Pancreatology. 2019;19:302-306. [PMID: 30737189 DOI: 10.1016/j.pan.2019.01.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
101 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
102 Park S, Kim JW, Kim H, Kim JW, Kim YJ, Lee KW, Kim JH, Kim JH, Hwang JH, Choi YR. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. APMIS. 2017;125:699-707. [PMID: 28556956 DOI: 10.1111/apm.12705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
103 Huang Z, Jiang Z, Zhao C, Han W, Lin L, Liu A, Weng S, Lin X. Simple and effective label-free electrochemical immunoassay for carbohydrate antigen 19-9 based on polythionine-Au composites as enhanced sensing signals for detecting different clinical samples. Int J Nanomedicine 2017;12:3049-58. [PMID: 28450781 DOI: 10.2147/IJN.S131805] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
104 Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu CT, Liu C, Long J, Xu J, Ni QX, Yu XJ. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery 2017;161:373-84. [PMID: 27838102 DOI: 10.1016/j.surg.2016.08.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
105 Kato T, Ban D, Tateishi U, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. J Hepatobiliary Pancreat Sci 2020;27:114-23. [PMID: 31702106 DOI: 10.1002/jhbp.700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32. [PMID: 31375338 DOI: 10.1016/j.hpb.2019.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
107 Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan Z, Qian Y, Huang Q, Ni Q, Luo G, Yu X. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Int J Oncol 2020;56:900-8. [PMID: 32319567 DOI: 10.3892/ijo.2020.4989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
108 Ren H, Wu CR, Aimaiti S, Wang CF. Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncol Lett 2020;19:4093-105. [PMID: 32382348 DOI: 10.3892/ol.2020.11495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Wang C, Xu R, Yuan Q, Wang Y, Shen D, Wang X, Gao W, Zhang H, Jiang H. Bioinformatics Method to Analyze the Mechanism of Pancreatic Cancer Disorder. Journal of Computational Biology 2013;20:444-52. [DOI: 10.1089/cmb.2012.0281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
110 Kang YM, Wang H, Li R, Pan G. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat 2021;20:15330338211043030. [PMID: 34617852 DOI: 10.1177/15330338211043030] [Reference Citation Analysis]
111 Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics 2020;10:5802-14. [PMID: 32483420 DOI: 10.7150/thno.44772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Gallego J, López C, Pazo-cid R, López-ríos F, Carrato A. Biomarkers in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1430-7. [DOI: 10.1007/s12094-017-1691-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
113 Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87:987-992. [PMID: 28803454 DOI: 10.1111/ans.14131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
114 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
115 Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430-438. [PMID: 23991810 DOI: 10.1111/hpb.12154] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 12.2] [Reference Citation Analysis]
116 Zhao Z, Zhao G, Yang S, Zhu S, Zhang S, Li P. The significance of exosomal RNAs in the development, diagnosis, and treatment of pancreatic cancer. Cancer Cell Int 2021;21:364. [PMID: 34243775 DOI: 10.1186/s12935-021-02059-8] [Reference Citation Analysis]
117 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, Sueda T. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014;110:422-429. [PMID: 24889968 DOI: 10.1002/jso.23666] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
118 Winer LK, Dhar VK, Wima K, Morris MC, Lee TC, Shah SA, Ahmad SA, Patel SH. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma. Journal of Surgical Research 2019;239:60-6. [DOI: 10.1016/j.jss.2019.01.061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
119 Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD. Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst 2013;138:410-6. [PMID: 23150876 DOI: 10.1039/c2an36128k] [Cited by in Crossref: 61] [Cited by in F6Publishing: 11] [Article Influence: 7.6] [Reference Citation Analysis]
120 Okabayashi T, Shima Y, Sumiyoshi T, Sui K, Iwata J, Morita S, Shimada Y, Iiyama T. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. Ann Surg Oncol 2018;25:1889-95. [PMID: 29691738 DOI: 10.1245/s10434-018-6485-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
121 You MS, Ryu JK, Huh G, Chun JW, Paik WH, Lee SH, Kim YT. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. World J Clin Oncol 2020; 11(9): 747-760 [PMID: 33033696 DOI: 10.5306/wjco.v11.i9.747] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
122 Kim MK, Woo SM, Park B, Yoon KA, Kim YH, Joo J, Lee WJ, Han SS, Park SJ, Kong SY. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem 2018;64:726-34. [PMID: 29352043 DOI: 10.1373/clinchem.2017.283721] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
123 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
124 McGahan W, Waterhouse MA, O'Connell DL, Merrett ND, Goldstein D, Wyld D, Burmeister EA, Jordan SJ, Neale RE. Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. Pancreatology 2020;20:1458-64. [PMID: 32868184 DOI: 10.1016/j.pan.2020.07.405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019;166:277-285. [PMID: 31272811 DOI: 10.1016/j.surg.2019.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
126 Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. Medicine (Baltimore) 2016;95:e3686. [PMID: 27175707 DOI: 10.1097/MD.0000000000003686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
127 Han ES, Lee HH, Lee JS, Song KY, Park CH, Jeon HM. At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment. J Gastric Cancer 2014;14:123-8. [PMID: 25061540 DOI: 10.5230/jgc.2014.14.2.123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
128 Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340-351. [PMID: 23331006 DOI: 10.2174/1566524011313030003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 97] [Article Influence: 2.1] [Reference Citation Analysis]
129 Wilcox CM, Kim H, Seay T, Varadarajulu S. Choice of plastic or metal stent for patients with jaundice with pancreaticobiliary malignancy using simple clinical tools: a prospective evaluation. BMJ Open Gastroenterol 2015;2:e000014. [PMID: 26462270 DOI: 10.1136/bmjgast-2014-000014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T, Fujita H, Hakamada K. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. Ann Surg Oncol 2021. [PMID: 34608555 DOI: 10.1245/s10434-021-10866-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
132 Banaei N, Foley A, Houghton JM, Sun Y, Kim B. Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay. Nanotechnology 2017;28:455101. [PMID: 28937361 DOI: 10.1088/1361-6528/aa8e8c] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 9.8] [Reference Citation Analysis]
133 Wang M, Hu M, Hu B, Guo C, Song Y, Jia Q, He L, Zhang Z, Fang S. Bimetallic cerium and ferric oxides nanoparticles embedded within mesoporous carbon matrix: Electrochemical immunosensor for sensitive detection of carbohydrate antigen 19-9. Biosens Bioelectron 2019;135:22-9. [PMID: 30991268 DOI: 10.1016/j.bios.2019.04.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 27] [Article Influence: 33.0] [Reference Citation Analysis]
134 Lee BM, Chung SY, Chang JS, Lee KJ, Seong J. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. Gut Liver 2018;12:342-52. [PMID: 29409306 DOI: 10.5009/gnl17216] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
135 Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015;136:2216-2227. [PMID: 25273947 DOI: 10.1002/ijc.29242] [Cited by in Crossref: 44] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
136 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021; 13(6): 472-494 [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
137 Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Int J Clin Oncol 2016;21:118-25. [DOI: 10.1007/s10147-015-0864-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
138 Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, Liu LM, Chen H. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med 2019;17:30. [PMID: 30658662 DOI: 10.1186/s12967-019-1782-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
139 Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013;31:1375-1383. [PMID: 23645398 DOI: 10.1007/s10637-013-9967-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
140 Mohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J, Cros J, Nicolle R, Iovanna J, Dusetti N, Mas E. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 2021;71:103541. [PMID: 34425307 DOI: 10.1016/j.ebiom.2021.103541] [Reference Citation Analysis]
141 Luo G, Liu C, Guo M, Long J, Liu Z, Xiao Z, Jin K, Cheng H, Lu Y, Ni Q, Yu X. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Cancer Letters 2017;385:46-50. [DOI: 10.1016/j.canlet.2016.10.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
142 Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, Büchler MW, Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 2019;45:1453-9. [PMID: 30981446 DOI: 10.1016/j.ejso.2019.03.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
143 Choi HJ, Kang CM, Lee WJ, Song SY, Cho A, Yun M, Lee JD, Kim JH, Lee JH. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J. 2013;54:1377-1383. [PMID: 24142641 DOI: 10.3349/ymj.2013.54.6.1377] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]